… previously exposed to sorafenib. While both trials were conducted before … on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. … Pharmaceuticals Inc; 2020. https://www.accessdata.fda.gov/drugsatfda_docs …

… drug approved by the FDA in 1999 for the treatment … synergistic antitumor activity with sorafenib in the MOLM14 AML … from the traditional herbal remedy dandelion, has been shown … Research of Zhejiang Chinese Medicine University for Affiliated Hospital …

… China; 5Graduate School, China Medical University, Shenyang, People’s … and other Phase 3 trials has made targeted therapy … the appropriate treatment based on the doctor’s recommendation … . Lenvatinib versus sorafenib in first-line treatment of patients with …

… compound isolated from the medicinal plant Artemisia annua. Extensive … migration.80 DHA Reduces Drug Resistance and Boosts … A Phase II clinical trial demonstrated that SRF plus … efficacy compared to sorafenib monotherapy. Treatment-related adverse events …

… ” in traditional Chinese medicine theory, which is … Derived Organoid Culture and Drug Treatment Fresh HCC tissues were … pharmacological mechanism of Xihuang pills in antitumor therapy. … , therapeutic hurdle confronting sorafenib and immune checkpoint inhibitors …

… design of future clinical trials and overcome clinical … as accessible complementary medicines for cancer treatment.42 Effects … 87 Sorafenib is approved by the Food and Drug Administration (FDA) … amplified ferroptosis. Front Bioeng Biotechnol. 2023;11:1171450. …

… who underwent TACE treatment at three medical institutions in … liver disease background, and treatment response. Therefore, the … in future prospective clinical trials. Conclusion The TPN … patients undergoing TACE plus sorafenib: a Chinese multicenter …

… retrieved from the institutional electronic medical records and reviewed retrospectively. … either as initial treatment or after local treatment failure), sorafenib was the most … enhance patient stratification for clinical trials, and help identify candidates …

… -001. Data from the trial supported the FDA’s fast track designation … were either nirogacestat (Ogsiveo; 75%), sorafenib (Nexavar; 50%), cytotoxic chemotherapy (41 … , for the treatment of desmoid tumors. News release. Parabilis Medicines. November 12 …

… against apoptosis, contributing to sorafenib resistance. Interventions that modulate … immune infiltration and attenuated treatment responses, illuminating the translational … collapse, thus overcoming conventional drug resistance mechanisms. Therapeutic …